Katsuaki Maehara: Key Clinical Trials Shaping Perioperative Chemo-Immunotherapy in NSCLC
Katsuaki Maehara/X

Katsuaki Maehara: Key Clinical Trials Shaping Perioperative Chemo-Immunotherapy in NSCLC

Katsuaki Maehara, Director of Medical Education Colleagues, shared on X:

“Perioperative chemo-immunotherapy. Updated the summary slide.

1. Title: Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer – The Neotorch Randomized Clinical Trial

Authors: Shun Lu, Wei Zhang, Lin Wu

Read the full article.

2. Title: Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

Authors: Mary O’Brien, Luis Paz-Ares, Sandrine Marreaud, Urania Dafni, Kersti Oselin, Libor Havel, Emilio Esteban, Dolores Isla, Alex Martinez-Marti, Martin Faehling, Masahiro Tsuboi, Jong-Seok Lee, Kazuhiko Nakagawa, Jing Yang, Ayman Samkari, Steven M. Keller, Murielle Mauer, Nitish Jha, Rolf Stahel, Benjamin Besse, Solange Peters.

Read the full article.

Katsuaki Maehara: Key Clinical Trials Shaping Perioperative Chemo-Immunotherapy in NSCLC

Then Dr. Maehara added:

“Another two phase II study of perioperative therapies.

Ivonescimab ± chemotherapy.”

Title: Perioperative ivonescimab with or without chemotherapy in resectable non-small cell lung cancer: a phase 2 trial.

Authors: Xiaoliang Zhao, Bin Zhang, Chenguang Li, Lianmin Zhang, Meng Wang, Ziqiang Tian, Shengguang Wang, Qiang Zhang, Huilai Lv, Chong Pang, Shiwang Wen, Xiaofei Wang, Wei Wei, Yu Zhang, Wuhao Huang, Jianquan Zhu, Yue Li, Chen Chen, Yao Tang, Bin Jia, Hua Zhang, Hui Chen, Sha Wang, Jiangyan Zhang, Wenting Li, Zhongmin Maxwell Wang, Baiyong Li, Michelle Xia, Zhenfa Zhang, Dongsheng Yue, Changli Wang.

Full paper.

Katsuaki Maehara

At the final part of series, Dr. Maehara posted:

Title: MDT-BRIDGE: Neoadjuvant Durvalumab Plus Chemotherapy Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy and Consolidation Durvalumab in Resectable or Borderline-resectable Stage IIB-IIIB NSCLC.

Authors: Martin Reck, Ernest Nadal, Nicolas Girard, Andrea Filippi, Linda Martin, Carl Gay, Cordula Petersen, Davina Gale, Ugochinyere Emeribe, Nefeli Georgoulia, Ignacio Diaz Perez, Jonathan Spicer.

Full paper.

Katsuaki Maehara

There are also another interesting figures featuring these studies, that you can see in the gallery below.

You can also read:

PEARLS/KEYNOTE-091 Final Analysis: Pembrolizumab Maintains Disease-Free Survival Benefit but Does Not Improve Overall Survival After Seven Years

Katsuaki Maehara: Key Clinical Trials Shaping Perioperative Chemo-Immunotherapy in NSCLC